Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52. Its price-book (P/B) ratio is 1.2, significantly cheaper than the industry average P/B of 5.81.
While it’s not Eli Lilly & Co. (NYSE: LLY) or Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) when it comes to growth, the company is still growing and generating profits. Value investors should take a closer look at this former high-flying blue-chip biotech stock.
